Barasertib (BioDeep_00001871585)

   


代谢物信息卡片


Barasertib

化学式: C26H31FN7O6P (587.2057368)
中文名称: 3-[[7-[3-[乙基[2-(磷酰氧基)乙基]氨基]丙氧基]-4-喹唑啉基]氨基]-N-(3-氟苯基)-1H-吡唑-5-乙酰胺, AZD1152
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCN(CCCOC1=CC2=C(C=C1)C(=NC=N2)NC3=NNC(=C3)CC(=O)NC4=CC(=CC=C4)F)CCOP(=O)(O)O
InChI: InChI=1S/C26H31FN7O6P/c1-2-34(10-12-40-41(36,37)38)9-4-11-39-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(35)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17H,2,4,9-12,15H2,1H3,(H,30,35)(H2,36,37,38)(H2,28,29,31,32,33)

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

同义名列表

3 个代谢物同义名

Barasertib; AZD-1152; AZD1152



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Jinhua Li, Ziqi Yan, Hongmei Li, Qiong Shi, Vidhula Ahire, Shenqiu Zhang, Naganna Nimishetti, Dun Yang, Thaddeus D Allen, Jing Zhang. The Phytochemical Scoulerine Inhibits Aurora Kinase Activity to Induce Mitotic and Cytokinetic Defects. Journal of natural products. 2021 08; 84(8):2312-2320. doi: 10.1021/acs.jnatprod.1c00429. [PMID: 34406008]
  • Donika Ivanova, Zhivko Zhelev, Dessislava Lazarova, Plamen Getsov, Rumiana Bakalova, Ichio Aoki. Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib. Anticancer research. 2018 03; 38(3):1407-1414. doi: 10.21873/anticanres.12364. [PMID: 29491065]
  • Serena Marchetti, Dick Pluim, Monique van Eijndhoven, Olaf van Tellingen, Roberto Mazzanti, Jos H Beijnen, Jan H M Schellens. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. Investigational new drugs. 2013 Oct; 31(5):1125-35. doi: 10.1007/s10637-013-9923-1. [PMID: 23315030]
  • Mike Dennis, Michelle Davies, Stuart Oliver, Roy D'Souza, Laura Pike, Paul Stockman. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. Cancer chemotherapy and pharmacology. 2012 Sep; 70(3):461-9. doi: 10.1007/s00280-012-1939-2. [PMID: 22864876]
  • Ron J Keizer, Anthe S Zandvliet, Jos H Beijnen, Jan H M Schellens, Alwin D R Huitema. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). Investigational new drugs. 2012 Aug; 30(4):1519-30. doi: 10.1007/s10637-011-9694-5. [PMID: 21626115]
  • Nicholas D Adams, Jerry L Adams, Joelle L Burgess, Amita M Chaudhari, Robert A Copeland, Carla A Donatelli, David H Drewry, Kelly E Fisher, Toshihiro Hamajima, Mary Ann Hardwicke, William F Huffman, Kristin K Koretke-Brown, Zhihong V Lai, Octerloney B McDonald, Hiroko Nakamura, Ken A Newlander, Catherine A Oleykowski, Cynthia A Parrish, Denis R Patrick, Ramona Plant, Martha A Sarpong, Kosuke Sasaki, Stanley J Schmidt, Domingos J Silva, David Sutton, Jun Tang, Christine S Thompson, Peter J Tummino, Jamin C Wang, Hong Xiang, Jingsong Yang, Dashyant Dhanak. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. Journal of medicinal chemistry. 2010 May; 53(10):3973-4001. doi: 10.1021/jm901870q. [PMID: 20420387]
  • Dick Pluim, Jos H Beijnen, Jan H M Schellens, Olaf van Tellingen. Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009 Nov; 877(29):3549-55. doi: 10.1016/j.jchromb.2009.08.035. [PMID: 19744901]
  • Jeffrey Cummings, Cassandra Hodgkinson, Rajesh Odedra, Patrizia Sini, Simon P Heaton, Kirsten E Mundt, Tim H Ward, Robert W Wilkinson, Jim Growcott, Andrew Hughes, Caroline Dive. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Molecular cancer therapeutics. 2008 Mar; 7(3):455-63. doi: 10.1158/1535-7163.mct-07-2136. [PMID: 18347133]
  • Robert P Evans, Claudia Naber, Tara Steffler, Tamara Checkland, Christopher A Maxwell, Jonathan J Keats, Andrew R Belch, Linda M Pilarski, Raymond Lai, Tony Reiman. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. British journal of haematology. 2008 Feb; 140(3):295-302. doi: 10.1111/j.1365-2141.2007.06913.x. [PMID: 18076711]